We serve Chemical Name:3-amino-3-furan-2-yl-propionic acid CAS:73456-99-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-amino-3-furan-2-yl-propionic acid
CAS.NO:73456-99-2
Synonyms:MFCD01014233;3-amino-3-furan-2-yl-propionic acid
Molecular Formula:C7H9NO3
Molecular Weight:155.15100
HS Code:2932190090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:253.5ºC at 760 mmHg
Density:1.286g/cm3
Index of Refraction:1.539
PSA:76.46000
Exact Mass:155.05800
LogP:1.45440
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like MFCD01014233 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-amino-3-furan-2-yl-propionic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD01014233 Use and application,3-amino-3-furan-2-yl-propionic acid technical grade,usp/ep/jp grade.
Related News: Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching. 3-amino-3-furan-2-yl-propionic acid manufacturer Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 3-amino-3-furan-2-yl-propionic acid supplier Some of Amanpour’s counterparts also offered well-wishes on Monday. 3-amino-3-furan-2-yl-propionic acid vendor Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 3-amino-3-furan-2-yl-propionic acid factory Some of Amanpour’s counterparts also offered well-wishes on Monday.
